Biophytis®

LIVE HEALTHIER LONGER

Paris, le 3 juin 2022

I Euronext : ALBPS – Nasdaq : BPTS

Forward Looking Statements

This presentation contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include statements regarding Biophytis' anticipated timing for its various Sarconeos (BIO101) clinical trials and expectations regarding commercialization. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, delays in patient recruitment or retention, interruptions in sourcing or supply chain, its ability to obtain the necessary regulatory authorizations, COVID-19-related delays, and the impact of the current pandemic on the Company's clinical trials. The forward-looking statements contained in this presentation are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please refer to the "Risk Factors" section of the Company's 2021 Full Year Financial Report available on BIOPHYTIS website (www.biophytis.com) and to the risks discussed in the Company's registration statement on Form F-1 and other reports filed with the Securities and Exchange Commission (the "SEC"). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Today's Corporate Highlights

- HQ location: Paris, France
- Founded: 2006
- Employees: 27 (May 30, 2022)
- Euronext growth (ALBPS) : July 2015
- Nasdaq (BPTS): February 2021
- Market cap: €20 M (May 30, 2022)
- Cash: €23.9 M as of June 30, 2021
- Key partner: Sorbonne University

Biophytis SA

- Is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the **degenerative processes associated with aging.**
- Our **small molecules** are aimed at stimulating **biological resilience** to stress during aging.

Sarconeos (BIO101)

- Our leading drug candidate is administered orally, for the treatment of mobility disability in elderly patients with **sarcopenia, with positive results** in a **Phase 2 clinical study (SARA)** completed in the United States and Europe.
- It is also being studied for the treatment of severe respiratory manifestations in **COVID-19 in a Phase 2-3 clinical study (COVA)** in Europe, Brazil, and the US.
- A pediatric formulation of Sarconeos (BIO101) is being developed with IND granted in the US and Belgium **(MYODA)** for the treatment of **Duchenne Muscular Dystrophy** (DMD).

Our Clinical Pipeline as of today



XXX : orphan diseases

Our strategic objectives

DEVELOP A PORTFOLIO OF DRUG CANDIDATES IN AGE-RELATED DISEASES, IN PARTICULAR MUSCULAR AND OPHTHALMOLOGICAL DISEASES

- Demonstrate the efficacy of Sarconeos (BIO101) in the treatment of sarcopenia
- Demonstrate the therapeutic benefit and obtain conditional approval of Sarconeos (BIO101) for COVID-19 patients
- Move forward with the development of our second molecule Macuneos (BIO201) in Age-Related Macular Degeneration (DMLA)

EXPLORE THE POTENTIAL OF OUR DRUG CANDIDATES IN ORPHAN NEUROMUSCULAR AND OPHTHALMOLOGICAL DISEASES

- Launch the clinical development of Sarconeos (BIO101) for the treatment of Duchenne muscular dystrophy

STRENGTHEN OUR PRESENCE IN THE UNITED STATES, THE LEADING BIOTECH/PHARMA MARKET

- Develop the company in the United States, in particular its clinical, regulatory and financial operations

- Forge partnerships with pharmaceutical laboratories to co-develop and market our drug candidates, in particular Sarconeos (BIO101)

Consolidation of our scientific expertise and strengthening of industrial property

RECOGNIZED SCIENTIFIC EXCELLENCE

9 scientific publications in peer-reviewed journals in 2021

- *Publications describing the mechanism of action, pharmacological effects or clinical development plans for Sarconeos or Macuneos*

4 scientific presentations in international congresses in 2021

- *July 2021 –* ECCMID: *Preclinical efficacy of BIO101 on respiratory function in SARS-CoV-2-infected Syrian hamsters. 31st European Congress of Clinical Microbiology & Infectious Diseases* - Online 9-11th July 2021
- *September 2021 –* WMS: - *In vivo effects of Sarconeos (API BIO101) on a mouse model of severe spinal muscular atrophy. 26th WMS Congress*, Online, Neuromuscular Disorders, Vol. 31: S131
- *October 2021 -* ICFSR: *Biophytis BIO101 in Sarcopenia: Lessons learned from the SARA program*. ICFSR 2021, Sept 29th – Oct 2nd. The Journal of Frailty & Aging
- *November 2021 –* Journée Française de Myologie: *Sarconeos (API BIO101) improves outcomes in a mouse model of severe spinal muscular atrophy*

A STRONGER PATENT PORTFOLIO

- A portfolio of **15 patent families** – in total **48** jointly owned patents granted and 48 jointly owned patent applications

- In 2021 a new patent pending

« Phytoecdysones and / or 20-hydroxyecdysone derivatives in combination with an active ingredient aimed at restoring SMN expression for their use in the treatment of spinal muscular atrophy »

Strengthening of the company's fundamentals over the past 18 months

VALIDATIONS OF THE THERAPEUTIC POTENTIAL OF SARCONEOS (BIO101)

COVA Study – COVID-19

- Part 2 interim analysis achieved in Q3 2021with positive DMC review to finalise the study without modification of the protocol (interim analysis of efficacy in the promising area, and satisfactory safety profile)
- Early Access Program (EAP) authorization in Brazil in February 2022
- 237 patients recruited in March 2022
- Early termination of patients' recruitment due to global drop of COVID-19 hospitalizations

SARA-INT Study – Sarcopenia

- Phase 2: positive top-line results on primary end-point (400-meter walk test) published in August 2021. Full results presented at the ICFSR 2021

IND Approval to start MYODA - DMD

- US IND & Belgium authorization obtained

STRENGTHENING OF THE FINANCIAL STRUCTURE (Nasdaq IPO)

- $20.1 million (€16.6 M) raise from Nasdaq IPO in February 2021
- €23.4 million raise in private placements on Euronext in 2021
- €23.9 million in cash and cash equivalents as of December 31, 2021
- ORNANE contract with Atlas to raise €32 million over 3 years

Growth in R&D costs and healthy financial situation

In €M	2020	2021
Research and developement expenses, net	(9.9)	(19.7)
General and administrative expenses	(4.0)	(7.1)
Operational loss	**(13.9)**	**(26.8)**
Net financial expense	(11.6)	(4.4)
Loss before taxes	**(25.5)**	**(31.2)**
Net loss	**(25.5)**	**(31.2)**

In €M	Dec. 31st,2020	Dec. 31st, 2021
Cash (banks and term deposits)	18.3	23.9
Shareholders' equity	2.3	5.7

Key milestones in the development of Sarconeos (BIO101)

	Achieved over the last 12 months	*Anticipated in the next 12 months*
COVA	• Interim analysis for Part 2 (155 patients) in Q3 2021 • Early Access Program (EAP) authorization in Brazil in February 2022 • Early termination of patient enrolment in April 2022	• Phase 2/3 study results expected in Q3 2022 • Application for conditional approval in Europe and the EUA in the US in 2023
SARA	• Positive topline study results in August 2021 • Full study results communicated during ICFSR in September 2021	• Regulatory agency meetings (FDA, EMA) in Q2/Q3 2022 • Start of Phase 2/3 study with 1st patient enrolled in H2 2022
MYODA	• US and Belgian IND regulatory approvals in Q1 2020 • Clinical batch production in 2021	• Study to start end of 2022 / beginning of 2023

Thank you

Contact investisseurs : investors@biophytis.com